cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.25402/fon.25012754.v1
title: Treatment patterns and costs among US patients with DLBCL not treated with 2L stem cell transplantation - supplementary material.docx

description: Supplementary Table 1. 1L treatmentSupplementary Table 2. 2L treatmentSupplementary Table 4. 4L treatmentSupplementary Table 5. Medical and pharmacy costs during the post-index period for all patients (PPPY)Supplementary Figure 1. Start of 2L therapy (index) by year for all patients (N = 750)Supplementary Figure 2. Prevalence (A) and mean number (B) of outpatient visits (PPPY)Supplementary Figure 3. Inpatient hospitalizations (A) prevalence, (B) mean length of inpatient stay (PPPY), and (C) mean number of inpatient visits (PPPY)Supplementary Figure 4. Emergency department visits (A) prevalence and (B) mean number of emergency department visits (PPPY)
DOI: 10.25549/examiner-c44-78444
title: Football, professional, 1959

description: 27 images. Football, professional, November 1 1959. Los Angeles Rams versus Chicago Bears. (Sleeve reads: SP-12700.); Caption slip reads: "Photographer: Jensen. Assignment: Rams vs. Bears. 1st quarter, 98/99: 12, Brat. to Casares, incomplete for Bears. 12 to Casares, complete fails to get a first down. 92/93: 15 kicks on 4th down, nearly blocked. Arnett gains 2 yards. 74/75: 24 scores. 76: J. Morris makes 3 yards to Ram 28. 77: Ed Brown makes 1st down to Ram 23. 72: 12 to J. Morris for 1st Chi touchdown. 2nd quarter, 73: Wade to Phillips complete. 48: Ram field goal by 40 -- misses. 49: Brat to McColl in end zone for incomplete pass. 23: Wade to Phillips complete to Ram 39 yd line. 24: Matson to Phillips in end zone incomplete. 82: Matson goes for 7 to Bear 41 yd line. 83: 12 to 47 for 16 yds to midfield for Bears. 29: Casares makes 6 yards to Ram 20 for 1st down Bears. 30: Matson goes to Bear 26 for 36 yd run. 3rd quarter, 62: Wade to SHofner for 22 yards to Ram 41. 63: Casares scores 2nd Bear TD from 1 yd line. 42: Matson goes 19 ydds for 2nd Ram TD. 43: Brown to Casares for Bears 4th TD 29 yds. 46: Thomas runs back kick off to midfield for Rams. 4th quarter, 47: Shofner misses pass in end zone. Barnes covering 15 threw it. 1: Clarke injured, coming off field. 2: Clarke on ground. 50: Wilson ran 50 yards to Bear 48 yd line for Rams. 51: Ryan to Arnett for 3rd Ram TD. 38 yds".; Supplementary material reads: "Los Angeles Rams (probable offensive starting lineup). Chicago Bears (probable offensive starting lineup)".
DOI: 10.25402/fon.25012844
title: Development and Validation of Algorithms for Identifying Lines of Therapy in Multiple Myeloma using Real-World Data - Supplementary material

description: Supplementary Table 1. Criteria for identifying CRAB symptoms and SCTSupplementary Table 2. Algorithm accuracy at predicting specific regimens in LOT1: aggregate populationSupplementary Table 3. Algorithm accuracy at predicting specific regimens in LOT1: SCT cohortSupplementary Table 4. Algorithm accuracy at predicting specific regimens in LOT1: non-SCT cohortSupplementary Table 5. Algorithm performance for regimens identified in LOT2, as verified by clinician review of unstructured information from electronic health recordsSupplementary Table 6. Algorithm performance for regimens identified in LOT3, as verified by clinician review of unstructured information from electronic health recordsSupplementary Table 7 Algorithm accuracy at predicting specific maintenance therapies used in LOT1: aggregate populationSupplementary Table 8. Algorithm accuracy at predicting specific maintenance therapies used in LOT1: SCT cohortSupplementary Table 9. Algorithm accuracy at predicting specific maintenance therapies used in LOT1: non-SCT cohortSupplementary Figure 1. Decision rules for identifying lines of therapy. A. Aggregate population. B. SCT cohort. C. Non-SCT cohort. FLT = first-line therapy; LOT = line of therapy; SCT = stem cell transplant.<br>
DOI: 10.25402/fon.25012844.v1
title: Development and Validation of Algorithms for Identifying Lines of Therapy in Multiple Myeloma using Real-World Data - Supplementary material

description: Supplementary Table 1. Criteria for identifying CRAB symptoms and SCTSupplementary Table 2. Algorithm accuracy at predicting specific regimens in LOT1: aggregate populationSupplementary Table 3. Algorithm accuracy at predicting specific regimens in LOT1: SCT cohortSupplementary Table 4. Algorithm accuracy at predicting specific regimens in LOT1: non-SCT cohortSupplementary Table 5. Algorithm performance for regimens identified in LOT2, as verified by clinician review of unstructured information from electronic health recordsSupplementary Table 6. Algorithm performance for regimens identified in LOT3, as verified by clinician review of unstructured information from electronic health recordsSupplementary Table 7 Algorithm accuracy at predicting specific maintenance therapies used in LOT1: aggregate populationSupplementary Table 8. Algorithm accuracy at predicting specific maintenance therapies used in LOT1: SCT cohortSupplementary Table 9. Algorithm accuracy at predicting specific maintenance therapies used in LOT1: non-SCT cohortSupplementary Figure 1. Decision rules for identifying lines of therapy. A. Aggregate population. B. SCT cohort. C. Non-SCT cohort. FLT = first-line therapy; LOT = line of therapy; SCT = stem cell transplant.<br>
DOI: 10.25402/fon.25013042
title: Real-world Comparative Effectiveness of Palbociclib Plus Aromatase Inhibitor in HR+/HER2− Metastatic Breast Cancer - Supplementary material

description: Table S1. Definitions of real-world tumor response.Table S2. Summary of study treatments (unadjusted population).Table S3. Reasons for discontinuing first-line treatment (unadjusted population).Table S4. Reason for censoring in OS and rwPFS analyses (nIPTW-adjusted population)Figure S1. Forest plot of overall survival by subgroup after PSMFigure S2. Forest plot for real-world progression-free survival by subgroup after PSM.
DOI: 10.25402/fon.25013042.v1
title: Real-world Comparative Effectiveness of Palbociclib Plus Aromatase Inhibitor in HR+/HER2− Metastatic Breast Cancer - Supplementary material

description: Table S1. Definitions of real-world tumor response.Table S2. Summary of study treatments (unadjusted population).Table S3. Reasons for discontinuing first-line treatment (unadjusted population).Table S4. Reason for censoring in OS and rwPFS analyses (nIPTW-adjusted population)Figure S1. Forest plot of overall survival by subgroup after PSMFigure S2. Forest plot for real-world progression-free survival by subgroup after PSM.
DOI: 10.25402/fon.25027577
title: Real-world safety of first-line immuno-oncology combination therapies for advanced non-small cell lung cancer - supplementary material

description: Supplementary Table 1. Exposure-adjusted adverse event rates
DOI: 10.25549/examiner-c44-81254
title: Foot Hill Freeway, 1955

description: 11 images. Foot Hill Freeway, 16 July 1955. Foothill freeway under construction at Devil's Gate dam; Freeway and new bridge over devil's gate dam; Freeway approaches to new bridge already in operation from La Canada on Northwest and Pasadena East.; Caption slip reads: "Photographer: Brett. Date: 1955-07-16. Reporter: Swaim. Assignment: Foothill freeway. K19, 20: Looking east across old and new Devil's Gate bridges, showing east approaches to new freeway. (without filter). K3,4: Same, with red filter. K21,22: Looking northwest from same spot toward La Canada, showing Flintridge approaches to bridge already in use. Muddy water is lake behind Devil's Gate dam. K23,24: Same, with red filter. K9,6: Straight overhead shots of deck of new bridge, with workmen preparing forms. Pix made from bucket swung on crane. K5: Looking up Devil's Gate gorge toward new structure."
DOI: 10.25402/fon.25027577.v1
title: Real-world safety of first-line immuno-oncology combination therapies for advanced non-small cell lung cancer - supplementary material

description: Supplementary Table 1. Exposure-adjusted adverse event rates
DOI: 10.25402/fon.25046366
title: The value of the accelerated approval pathway: Real-world outcomes associated with reducing the time between innovations - supplementary material

description: Supplementary table 1. Patient selection and attrition.Supplementary table 2. Patient characteristics.Supplementary table 3. Proportion of patients surviving to the AA date in real-world database and population level.Supplementary figure
DOI: 10.25549/examiner-c44-81094
title: Furniture Mart Exhibit, 1955

description: 6 images. Furniture Mart Exhibit, 11 July 1955. Patti Fosdick; Frida Nilsen; Beth Crowl.; Caption slip reads: "Photographer: B Gray. Date: 1955-07-11. Reporter: J. Massard. Assignment: Furniture Mart Exhibit. 27 & 28: Patti Fosdick demonstrates silicone-treated fabric which repells ink. 3, 4, & 38: Frida Nilsen sits on table of roll-top dining table which comes in compact bureau with four chairs and linen space. 5 & 6: Beth Crowl and miniature train cocktail table."
DOI: 10.25402/fon.25046366.v1
title: The value of the accelerated approval pathway: Real-world outcomes associated with reducing the time between innovations - supplementary material

description: Supplementary table 1. Patient selection and attrition.Supplementary table 2. Patient characteristics.Supplementary table 3. Proportion of patients surviving to the AA date in real-world database and population level.Supplementary figure
DOI: 10.25402/fon.25070762
title: Metastatic Castration Resistant Prostate Cancer (mCRPC) patients' experience with Radium-223 treatment in Japan - Supplementary Material

description: Supplementary Table s1: Laboratory parametersSupplementary Table s2: Completion Rate of Ra-223 cyclesSupplementary Table s3: Information QuestionnaireSupplementary Table s4. Minimally important difference (MID) for PRO scales.
DOI: 10.25402/fon.25070762.v1
title: Metastatic Castration Resistant Prostate Cancer (mCRPC) patients' experience with Radium-223 treatment in Japan - Supplementary Material

description: Supplementary Table s1: Laboratory parametersSupplementary Table s2: Completion Rate of Ra-223 cyclesSupplementary Table s3: Information QuestionnaireSupplementary Table s4. Minimally important difference (MID) for PRO scales.
DOI: 10.25549/examiner-c44-78683
title: Baby elephants, 1954

description: 9 images. Baby elephants, May 3 1954. Eight baby elephants arrive aboard American President Harding; Consigned here for Catalina Wild Life Expeditions; Rickey Johnson -- 6 years (son of Captain Johnson, skipper of President Harding).; Supplementary material reads: "Gershon. City desk. Illus. Eb phants. Eight baby elephants ranging from 9 months to 2 years arrived here yesterday on boar [sic.] the American President Line freighter President Harding. They were consigned to Noel Rosefelt, president of Catalina Wild Life Expeditions. Rickey Johnson, 8, son of Capt. Carl Johnson, skipper of the President Harding was on hand and had an 'elephant show of his own' when he was permitted to feed, pet and ride the pachyderms. His father also joined in the fun. 'Tuffy,' one of the babies didn't like his crate and is shown in several efforts to climb out".
DOI: 10.25402/fon.25133420
title: Real-World Clinical Scenarios During Introduction of Trastuzumab Biosimilar for HER2-Positive Breast Cancer in the EU - Supplementary Material

description: Supplementary Table S1. Summary of site characteristics. Supplementary figure 1
DOI: 10.25402/fon.25133420.v1
title: Real-World Clinical Scenarios During Introduction of Trastuzumab Biosimilar for HER2-Positive Breast Cancer in the EU - Supplementary Material

description: Supplementary Table S1. Summary of site characteristics. Supplementary figure 1
DOI: 10.25549/examiner-c44-48428
title: Saint Nicholas Junior League Girls planning party at the home of Mrs. Fred Andrews, 626 North Las Palmas, 1952

description: 4 images. Saint Nicholas Junior League Girls planning party at the home of Mrs. Fred Andrews, 626 North Las Palmas, 24 January 1952. Carole Freiderich; Joyce Soba; Marion Haddad; Sharlene Shoheen; Ginger Ghiz; Pat Sawoya; Lorraine Sawoya; Deanne Soliba. (Sleeve reads: S-9548).; Caption slip reads: "Photographer: Paegel. Date: 01-24. Assignment: 626 No. Las Palmas. 11-12, Left to right: Carole Freiderich; Joyce Soba; Marion Haddad; rear: Sharlene Shoheen. 19-20, 1st row: Ginger Ghiz; Carole Freiderich; Marion Haddad. 2nd row: Pat Sowaya; Deanne Soliba. Standing: Joyce Soba; Lorraine Sowaya; Sharlene Shoheen".; Supplementary material reads: "Photo assignmentfor Thursday January 24 at 8 p.m. Pls. go to home of Mrs. Fred Andrews, 626 North Las Palmas, HI 7511, get shots of St. Nicholas Junior League girls planning party. Candid, three and five cols. Contacts Friday. Thanks, Carter Ludlow".
DOI: 10.25402/fon.25133483
title: TREATMENT PATTERNS, HEALTHCARE RESOURCE UTILIZATION, AND OUTCOMES FOR EARLY STAGE TRIPLE-NEGATIVE BREAST CANCER IN JAPAN - supplementary material

description: <b>Table S1. </b>List of anti-HER2 and hormone therapies<b>Figure S2.</b> Patient disposition (hospital claims data)<b>Figure S3.</b> Patient disposition (health insurance claims data)<b>Figure S4</b>. Kaplan–Meier plots of overall survival in patients with early stage breast cancer (Groups 1 and 2)<b>Figure S5</b>. Kaplan–Meier plots of event-free survival in patients with early stage breast cancer (Groups 1 and 2)
DOI: 10.25402/fon.25133483.v1
title: TREATMENT PATTERNS, HEALTHCARE RESOURCE UTILIZATION, AND OUTCOMES FOR EARLY STAGE TRIPLE-NEGATIVE BREAST CANCER IN JAPAN - supplementary material

description: <b>Table S1. </b>List of anti-HER2 and hormone therapies<b>Figure S2.</b> Patient disposition (hospital claims data)<b>Figure S3.</b> Patient disposition (health insurance claims data)<b>Figure S4</b>. Kaplan–Meier plots of overall survival in patients with early stage breast cancer (Groups 1 and 2)<b>Figure S5</b>. Kaplan–Meier plots of event-free survival in patients with early stage breast cancer (Groups 1 and 2)
DOI: 10.25402/fon.25218032
title: Clinical outcomes for previously treated patients with advanced biliary tract cancer - supplementary material

description: Supplemental Table 1: Search strategy for Embase (Embase 1974 to 2021 June 28)Supplemental Table 2: Search strategy for MEDLINE (Ovid MEDLINE In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to June 28, 2021)Supplemental Table 3: Search strategy for CENTRAL (EBM Reviews - Cochrane Central Register of Controlled Trials May 2021)Supplemental Table 4: Search strategy for American Society of Clinical Oncology conference abstracts (Northern Light Life Sciences Conference Abstracts 2010 to 2021 Week 24)Supplemental Table 5: Search strategy for European Society for Medical Oncology conference abstracts (Northern Light Life Sciences Conference Abstracts 2010 to 2021 Week 24)Supplemental Table 6: Search strategy for ClinicalTrials.govSupplemental Table 7: Detailed study characteristics for trials included in the systematic reviewSupplemental Table 8: Detailed treatment characteristics for trials included in the systematic reviewSupplemental Table 9: Detailed patient characteristics for trials included in the systematic reviewSupplemental Table 10: Response outcomes for trials included in the systematic reviewSupplemental Table 11: Survival outcomes for trials included in the systematic reviewSupplemental Table 12: Safety outcomes for trials included in the systematic reviewSupplemental Table 13: Patient-reported outcomes for trials included in the systematic reviewSupplemental Table 14: Quality assessment of included single-arm and non-randomized trialsSupplemental Table 15: Summary of pooled KM estimates of OS Supplemental Table 16: Summary of KM estimates of PFS Supplemental Figure 1: Risk of bias assessment of included RCTs
DOI: 10.25402/fon.25218032.v1
title: Clinical outcomes for previously treated patients with advanced biliary tract cancer - supplementary material

description: Supplemental Table 1: Search strategy for Embase (Embase 1974 to 2021 June 28)Supplemental Table 2: Search strategy for MEDLINE (Ovid MEDLINE In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to June 28, 2021)Supplemental Table 3: Search strategy for CENTRAL (EBM Reviews - Cochrane Central Register of Controlled Trials May 2021)Supplemental Table 4: Search strategy for American Society of Clinical Oncology conference abstracts (Northern Light Life Sciences Conference Abstracts 2010 to 2021 Week 24)Supplemental Table 5: Search strategy for European Society for Medical Oncology conference abstracts (Northern Light Life Sciences Conference Abstracts 2010 to 2021 Week 24)Supplemental Table 6: Search strategy for ClinicalTrials.govSupplemental Table 7: Detailed study characteristics for trials included in the systematic reviewSupplemental Table 8: Detailed treatment characteristics for trials included in the systematic reviewSupplemental Table 9: Detailed patient characteristics for trials included in the systematic reviewSupplemental Table 10: Response outcomes for trials included in the systematic reviewSupplemental Table 11: Survival outcomes for trials included in the systematic reviewSupplemental Table 12: Safety outcomes for trials included in the systematic reviewSupplemental Table 13: Patient-reported outcomes for trials included in the systematic reviewSupplemental Table 14: Quality assessment of included single-arm and non-randomized trialsSupplemental Table 15: Summary of pooled KM estimates of OS Supplemental Table 16: Summary of KM estimates of PFS Supplemental Figure 1: Risk of bias assessment of included RCTs
DOI: 10.25549/examiner-c44-79307
title: Honoring Oscar Smith, 1954

description: 4 images. Honoring Oscar Smith, September 30 1954. Oscar Smith (retiring president of Pacific Electric receives scroll from Roger Jessup); Roger Jessup (supervisor); Roly Nall (past president, international president of Optimistic Club).; Caption slip reads: "Photographer: Mitchell. Date: 1954-09-30. Assignment: Optimist luncheon honoring Oscar Smith. L. to r., 59/60: Oscar A. Smith retiring pres. of Pacific Electric receives scroll from supervisor Roger Jessup. 57/58: Oscar A. Smith retiring pres. of Pacific Elec. receives scroll from Roly Nall past pres. international pres. of the Optimist Club".
DOI: 10.25402/fon.25257016
title: Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumor in the United States - supplementary material

description: Supplementary Table 1. Distribution and comparison of ICD-10-CM diagnosis codes on the index date or during the minimum 6-month pre-index period<sup>1 </sup>in the pexidartinib cohort (N=82) and the other systemic therapy cohort indexed at any time (N=462).Supplementary Table 2. Demographics and select baseline clinical characteristics of patients indexed on other systemic therapies for TGCT before August 2, 2019 (N=199).
DOI: 10.25402/fon.25257016.v1
title: Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumor in the United States - supplementary material

description: Supplementary Table 1. Distribution and comparison of ICD-10-CM diagnosis codes on the index date or during the minimum 6-month pre-index period<sup>1 </sup>in the pexidartinib cohort (N=82) and the other systemic therapy cohort indexed at any time (N=462).Supplementary Table 2. Demographics and select baseline clinical characteristics of patients indexed on other systemic therapies for TGCT before August 2, 2019 (N=199).
DOI: 10.25549/examiner-c44-78930
title: Richard Haymes, 1954

description: 8 images. Richard Haymes, 25 June 1954. Bartley Crum; Richard Haymes; Albert Del Guercio (Deputy Director U.S. Immigration); David C. Marcus; Atty. S.S. Schwartz.; Caption slip reads: "Photographer: Paegel. Date: 1954-06-25. Reporter: Devlin. 45: Bartley Crum; Richard Haymes. 25: Bartley Crum; Richard Haymes; Albert Del Guercio, Dep. Director, U.S. immigration. 38: Dick Haymes; David C. Marcus; Richard R. Cody; S.S. Schwartz".
DOI: 10.25549/examiner-c44-55258
title: Los Angeles City Police Crime Laboratory feature, 1955

description: 12 images. Los Angeles City Police Crime Laboratory feature, 13 April 1955. Ray Pinker (Chief Criminalist); William Penprase (Police chemist); Sergeant Jay Allen; Sergeant Daniel McCauley; Dewayne Wolfer (Firearms expert); Warren M. Stilson; Officer Lee Jones.; Caption slip reads: "Photographer: Gray. Date: 04-13. Reporter: Adler. Assignment: Crime Lab. Monday. 8: Firearms Identification Expert Dewayne Wolfer examining fired cartridge case in comparison microscope, while Capt. Warren M. Stilson, commander of LAPD's Scientific Investigation Division, examines gun. 2/3/4/, l to r: Capt. Warren M. Stilson; Lt. Lee Jones, assist commander of Scientific Investigation Division, and Chief Criminalist Ray Pinker in Pinker's new office and laboratory in the new Police Building. 23, front to back: Lt. Lee Jones; Ray Pinker and Capt. Warren Stilson in new building's negative file room. 27/28: Chief Criminalist Ray Pinker at his overloaded desk in the present Crime Lab in the old Central Jail. 37/38: Chief Criminalist Ray Pinker at his desk in present quarters, with Police Chemist William Penprase working on a titration in the background -- note crammed office--laboratory. 25/26, l to r: Sgt. Jay Allen examining spectographic film while Sgt. Daniel McCauley makes a spectographic analysis in tiny present quarters. 7: Firearms Identification Expert Dewayne Wolfer examining fired cartridge cases in a comparison microscope. 24: Shots looking along hallway on fourth floor of new Police Building, the floor occupied by LAPD's Scientific Investigation Division".
DOI: 10.25402/fon.25304077
title: Elranatamab Efficacy in MagnetisMM-3 Compared with Real-World Control Arms in Triple-Class Refractory Multiple Myeloma - supplementary material

description: Supplementary Table 1. Most common physician’s choice treatment regimens observed in COTA and FH databases.Supplementary Table 2. Restricted mean survival time comparison of progression-free survival and overall survival between patients receiving elranatamab in the MagnetisMM-3Cohort A and physician’s choice in the COTA real-world external control arm.Supplemental Figure 1. Progression-free survival differences between patients receiving elranatamab in MagnetisMM-3 and real-world physician’s choice in the FH database, after applying multiple imputation and IPT weighting.Supplemental Figure 2. Overall survival differences between patients receiving elranatamab in MagnetisMM-3 and real-world physician’s choice in the FH database, after applying multiple imputation and IPT weighting.
DOI: 10.25402/fon.25304077.v1
title: Elranatamab Efficacy in MagnetisMM-3 Compared with Real-World Control Arms in Triple-Class Refractory Multiple Myeloma - supplementary material

description: Supplementary Table 1. Most common physician’s choice treatment regimens observed in COTA and FH databases.Supplementary Table 2. Restricted mean survival time comparison of progression-free survival and overall survival between patients receiving elranatamab in the MagnetisMM-3Cohort A and physician’s choice in the COTA real-world external control arm.Supplemental Figure 1. Progression-free survival differences between patients receiving elranatamab in MagnetisMM-3 and real-world physician’s choice in the FH database, after applying multiple imputation and IPT weighting.Supplemental Figure 2. Overall survival differences between patients receiving elranatamab in MagnetisMM-3 and real-world physician’s choice in the FH database, after applying multiple imputation and IPT weighting.
DOI: 10.25402/fon.25311598
title: The major issue of oncological treatment administration at the end of life: a retrospective study - supplementary material

description: Supplementary table S1: Clinicopathological features of study case seriesSupplementary Table S3: Univariate analysis of variable potential predicting end-of-life therapy